1. Albertsen PC, Hanley JA, Fine J et al (2005) Twenty-year outcomes following conservative management of clinically localized prostate cancer. J Am Med Ass (JAMA) 293:2095–2101
2. Bander NH, Trabulsi EJ, Kostakoglu L et al (2003) Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 170:1717–1721
3. Bastian PJ, Waha A, Müller StC, von Rücker A (2004) Epigenetische Veränderungen in der Karzinogenese des Prostatakarzinoms. Dtsch Ärztebl 101:A1981–1985
4. Baum RP, Hertel A, Baew-Christow T et al (1991) First clinical results with a Tc-99m labeled monoclonal anti-AFP antibody in germ cell and liver tumours (FP-2G3-5). Eur J Nucl Med 18:535
5. Baum RP, Hertel A, Baew-Christow T, Boeckmann W, Hör G, Goldenberg DM (1991) Initial clinical results with a Tc-99m labeled anti-AFP monoclonal antibody fragment in germ cell and liver tumours (Abstr. 613 ). J Nucl Med 32:1053